Intelligent Bio Solutions Subsidiary Broadens Intellectual Property Portfolio with Grant of New European Patent with Unitary Effect for Innovative Intelligent Fingerprinting DSR-Plus Cartridge Reader
11 Aprile 2024 - 2:30PM
Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq:
INBS), a medical technology company delivering intelligent, rapid,
non-invasive testing solutions, today announced the broadening of
the intellectual property portfolio of its wholly owned subsidiary,
Intelligent Fingerprinting Limited, with the grant of a new
European patent with unitary effect for its ground-breaking
DSR-Plus Cartridge Reader. This latest achievement follows the
successful protection of the same technology in the United Kingdom
and marks another significant milestone in the Company’s expansion
and protection of its intellectual property.
The European patent further confirms the
uniqueness and innovation of the technology behind the DSR-Plus
Cartridge Reader. The DSR-Plus Cartridge Reader, known for its
proprietary technology in drug screening through fingerprint sweat
analysis, provides a non-invasive and rapid method designed to
accurately detect drug use. This technology is particularly
valuable in workplaces and safety-critical industries, offering a
discreet and hygienic testing solution.
With the European patent secured, the Company
leveraged the new streamlined unitary patent scheme to bring the
patent into effect in 17 European countries. This strategic move
underscores the Company’s commitment to expanding its global
footprint and offering advanced solutions to a broader market.
Harry Simeonidis, President and CEO at
Intelligent Bio Solutions, commented, “The grant of the European
patent is a testament to the ingenuity and hard work of our team.
It fortifies our intellectual property portfolio and paves the way
for our expansion into the European market. We are excited about
the prospects of bringing our innovative technology to more
organizations and contributing to safer and healthier workplaces
across Europe.”
The DSR-Plus Cartridge Reader, designed for
simplicity and efficiency, collects sweat samples from fingerprints
in under a minute and delivers results in less than ten minutes.
This innovative approach is revolutionizing drug screening
practices, offering a dignified and effective alternative to
conventional methods.
Visit INBS’ website for more information about
Intelligent Fingerprinting and the DSR-Plus Cartridge
Reader.
About Intelligent Bio Solutions
Inc.Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a
medical technology company delivering innovative, rapid,
non-invasive testing solutions. The Company believes that its
Intelligent Fingerprinting Drug Screening System will revolutionize
portable testing through fingerprint sweat analysis, which has the
potential for broader applications in additional fields. Designed
as a hygienic and cost-effective system, the test screens for
recent use of drugs commonly found in the workplace, including
opiates, cocaine, methamphetamine, and cannabis. With sample
collection in seconds and results in under ten minutes, this
technology would be a valuable tool for employers in
safety-critical industries. Additionally, the Company's biosensor
platform has the potential to test for up to 130 indications,
ranging from glucose to immunological conditions and communicable
diseases. The Company's current customer segments include
construction, manufacturing and engineering, transport and
logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, Intelligent Bio
Solutions Inc.’s ability to successfully develop and commercialize
its drug and diagnostic tests, realize commercial benefit from its
partnerships and collaborations, and secure regulatory approvals,
among others. Although Intelligent Bio Solutions Inc. believes that
the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Intelligent Bio Solutions Inc. has
attempted to identify forward-looking statements by terminology,
including “believes,” “estimates,” “anticipates,” “expects,”
“plans,” “projects,” “intends,” “potential,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, included in Intelligent Bio Solutions’ public filings
filed with the Securities and Exchange Commission. Any
forward-looking statements contained in this release speak only as
of its date. Intelligent Bio Solutions undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Company Contact:Intelligent Bio Solutions
Inc.info@ibs.incLinkedIn | Twitter
Investor & Media Contact:Valter Pinto,
Managing DirectorKCSA Strategic CommunicationsPH: (212)
896-1254INBS@kcsa.com
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Giu 2023 a Giu 2024